Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Advanced Solid Tumor
- Cervical Cancer
- Esophageal Squamous Cell Carcinoma
- Hepatocellular Carcinoma
- Merkel Cell Carcinoma
- Mesothelioma
- MSI-H/dMMR Tumors
- Nasopharyngeal Carcinoma
- PD-L1 Amplified Tumor (9p24.1)
- Urothelial Carcinoma
- Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: The study consists of 2 parts. Part 1 is a dose-escalation design to identify the maximum tolerant dose and/or pharmacologically active dose for INCB099280. Part 2 is an expansion at 1 or more dose levels to further explore safety, preliminary efficacy, pharmacokinetic, and pharmacodynamic effects.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04242199
- Collaborators
- Not Provided
- Investigators
- Study Director: Wolfram Dempke, MD Incyte Corporation
Get Well Soon